%0 Journal Article
%A Babaei, Masoud
%A Balavarca, Yesilda
%A Jansen, Lina
%A Lemmens, Valery
%A van Erning, Felice N
%A van Eycken, Liesbet
%A Vaes, Evelien
%A Sjövall, Annika
%A Glimelius, Bengt
%A Ulrich, Cornelia M
%A Schrotz-King, Petra
%A Brenner, Hermann
%T Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study.
%J International journal of cancer
%V 142
%N 7
%@ 0020-7136
%C Bognor Regis
%I Wiley-Liss
%M DKFZ-2018-00144
%P 1480 - 1489
%D 2018
%X The advantage of adjuvant chemotherapy (ACT) for treating Stage III colon cancer patients is well established and widely accepted. However, many patients with Stage III colon cancer do not receive ACT. Moreover, there are controversies around the effectiveness of ACT for Stage II patients. We investigated the administration of ACT and its association with overall survival in resected Stage II (overall and stratified by low-/high-risk) and Stage III colon cancer patients in three European countries including The Netherlands (2009-2014), Belgium (2009-2013) and Sweden (2009-2014). Hazard ratios (HR) for death were obtained by Cox regression models adjusted for potential confounders. A total of 60244 resected colon cancer patients with pathological Stages II and III were analyzed. A small proportion (range 9-24
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29159866
%R 10.1002/ijc.31168
%U https://inrepo02.dkfz.de/record/132456